Holocene Advisors
BLTE

Holocene Advisors’s Belite Bio BLTE Stock Holding History

Holocene Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.8M Buy
494,495
+410,428
+488% +$69M 0.19% 134
2025
Q4 		$13.4M Buy
+84,067
New +$9.96M 0.03% 310

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Holocene Advisors's BLTE Position: Q1 2026 in Review

Holocene Advisors increased its Belite Bio (BLTE) stake by 488% in Q1 2026, buying an estimated $69M and bringing the position to 494,495 shares worth $78.8M. The position accounts for 0.19% of the portfolio, ranked #134.

Holocene Advisors first reported a position in BLTE in Q4 2025 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Holocene Advisors held 494,495 shares of Belite Bio worth $78.8M as of Q1 2026.
  • Holocene Advisors bought 410,428 Belite Bio shares in Q1 2026, an estimated $69M.
  • Belite Bio made up 0.19% of Holocene Advisors's portfolio in Q1 2026, its #134 holding.
  • Holocene Advisors first reported a position in Belite Bio in Q4 2025 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.